Hypothesis

Individuals with higher pain tolerance (higher thermal and mechanical thresholds) possess greater epigenetic plasticity, which translates into increased efficiency of somatic cell reprogramming to induced pluripotent stem cells and better endurance‑type athletic performance. Conversely, low pain tolerance reflects a rigid epigenome that resists reprogramming and predicts poorer performance outcomes.

Mechanistic rationale

• Pain perception is modulated by vagal tone and mitochondrial ROS production, both of which influence chromatin accessibility through NAD⁺‑dependent sirtuin activity and histone acetylation states.
• High pain tolerance is associated with elevated vagal activity and improved mitochondrial respiration, fostering a permissive chromatin environment that facilitates the opening of pluripotency gene promoters (OCT4, SOX2, KLF4, cMYC) during reprogramming.
• Low pain tolerance coincides with chronic low‑grade inflammation, heightened C‑reactive protein, and increased HDAC activity, leading to a more condensed epigenome that impedes factor binding and reduces reprogramming yield.
• The same chromatin state influences muscle gene expression and recovery pathways, linking nociceptive phenotype to aerobic capacity and time‑to‑exhaustion in endurance tests.

Testable predictions

1. In a cohort of healthy adults, quantitative sensory testing (QST) will reveal a positive correlation between pain threshold (°C for heat, mN for pressure) and the number of iPSC colonies derived from peripheral blood mononuclear cells after exposure to defined reprogramming factors.
2. The epigenetic age of the resulting iPSCs, assessed by DNAmGrimAge, will be inversely related to the donor's pain threshold; higher tolerance yields iPSCs with younger epigenetic ages.
3. Pain threshold will predict VO₂ max and treadmill time‑to‑exhaustion, with each 1 °C increase in heat pain threshold associated with ~3 % higher VO₂ max after adjusting for age, sex, and training status.
4. Pharmacological elevation of vagal tone (e.g., transcutaneous vagus nerve stimulation) will raise pain thresholds, increase reprogramming efficiency in vitro, and improve endurance performance in a crossover trial.

Falsifiable outcomes

• If no significant correlation exists between pain threshold and iPSC colony formation (p > 0.05 after multiple‑test correction), the hypothesis is refuted.
• If iPSC epigenetic age shows no relationship to pain sensitivity, or if inflammation markers confound the association beyond what vagal tone explains, the mechanistic link is unsupported.
• If endurance performance does not improve with experimentally increased pain tolerance, the proposed performance link is invalid.

Experimental design outline

• Recruit 120 participants stratified by age (20‑40, 41‑60 years) and sex.
• Measure heat and pain pressure thresholds using a thermode and algometer.
• Collect peripheral blood, isolate mononuclear cells, and reprogram with Sendai‑virus OCT4/SOX2/KLF4/cMYC.
• Count alkaline‑positive colonies at day 14; compute reprogramming efficiency (colonies per 10⁴ input cells).
• Extract DNA from iPSCs, run Illumina EPIC array, calculate DNAmGrimAge.
• Conduct cardiopulmonary exercise test to obtain VO₂ max and time to exhaustion at 80 % VO₂ max.
• Analyze data with linear mixed models, including covariates (chronological age, BMI, training hours, CRP).
• In a sub‑study, apply transcutaneous vagus nerve stimulation for 20 min daily over two weeks, repeat QST, reprogramming assay, and exercise test.

By integrating nociceptive phenotyping with epigenetic plasticity assays and functional performance measures, this framework directly tests whether pain tolerance serves as a readable proxy for the cell’s capacity to reset its epigenome and sustain high‑intensity output.